Myrmecia pilosula venom (JJA venom)

Myrmecia pilosula venom is a complex biological mixture produced by the Australian Jack Jumper Ant, primarily composed of allergenic proteins and cytolytic peptides known as pilosulins (PMID: 11544378). The venom is clinically significant due to its high potential to induce severe, life-threatening anaphylaxis in sensitized individuals, particularly in southeastern Australia (PMID: 12513387). The major allergens, Myr p 1, Myr p 2, and Myr p 3, are the primary targets for diagnostic testing and therapeutic intervention (WHO/IUIS Allergen Nomenclature). In a clinical setting, the venom is utilized as a therapeutic agent in allergen immunotherapy (AIT) to desensitize patients by modulating the immune system's response to future stings. This process involves the induction of regulatory T cells and the production of IgG4 antibodies to neutralize the venom's effects (PMID: 21838918). Beyond its allergenic properties, the venom's pilosulin components exhibit potent antimicrobial and cytolytic activities by disrupting cell membranes (PMID: 11544378). Research into these peptides suggests potential applications in developing new anti-infective or anti-tumor agents, although their primary medical relevance remains in allergy management.

Other names

Jack Jumper Ant venomHopper ant venomMyr p venomMyrmecia pilosula venom extract

Allergen immunotherapy (AIT) using Myrmecia pilosula venom induces immunological tolerance by shifting the immune response from a Th2-mediated allergic profile to a Th1-mediated or regulatory T cell-mediated profile, and by increasing the production of allergen-specific IgG4 blocking antibodies (PMID: 12513387, PMID: 21838918).